This study is currently recruiting.
This study is being conducted by Dr. Stephanie Morris and Dr. Jodi Lindsey to evaluate if the study drug KZ101, also known as suramin sodium, helps to reduce symptoms related to social impairment and adaptive functioning in male children with autism spectrum disorder ages 5 to 14 years old. The length of the study is approximately 30 weeks and consists of 12 onsite visits.
Eligibility & Criteria
IRB #: IRB00473966
Principal Investigator: Stephanie Morris, MD
Eligible Age Range: 5-14 years
Gender: Male
Diagnosis: Autism